Lanean...
A Phase I Study of Bevacizumab (B) in Combination with Everolimus (E) and Erlotinib (E) in Advanced Cancer (BEE)
PURPOSE: VEGF, mTOR, and EGFR inhibitors have demonstrated anti-tumor and anti-angiogenic effects alone and in combination with each other. This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus and erlotinib combination. METHODS: Doublet therapy consisted of...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2010
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4086252/ https://ncbi.nlm.nih.gov/pubmed/21079958 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1507-6 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|